InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
3
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-35.5%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Kellen Scott, Chief Financial Officer. Officer active across 1 company, notably DiaMedica Therapeutics Inc.. Cumulatively, 3 reports have been recorded. Breakdown: 3 buys · 0 sell. Total volume traded: €89k. History available since 16 August 2021. The latest transaction was disclosed on 23 June 2023 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations3 total
10,000 shares@ US$3.9140.0% of flowVoting Common Shares, no par value per shareSEC:0001235802-23-000070:0
Ideal exit: 19 Mar 2024 (T+270)
10,000 shares@ US$3.146330.0% of flowVoting Common Shares, no par value per shareSEC:0001235802-21-000097
Ideal exit: 13 May 2022 (T+270)
10,000 shares@ US$3.14630.0064% mcap50.0% of flowVoting Common Shares, no par value per shareSEC:0001235802-21-000097:0
Ideal exit: 13 May 2022 (T+270)
3 of 3 declarations
About Kellen Scott
Kellen Scott serves as the Chief Financial Officer and Secretary of DiaMedica Therapeutics Inc. In this role, he is responsible for the financial management of the company, including financial planning, risk management, and financial compliance. Kellen brings significant expertise in finance and plays a key role in DiaMedica's financial strategy, a company focused on developing treatments for neurological diseases.
